



Discovery Fueled by Ultra-Sensitivity

Quanterix To Participate at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Nov 13, 2023

BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 13, 2023-- [Quanterix Corporation](#) (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will speak in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 16, 2023 at 3:00 PM ET. To access the live webcast, please register [here](#). A replay will be available following the conference on Quanterix's website here: [ir.quanterix.com](#).

To learn more about Quanterix, visit [www.quanterix.com/company/](#). To learn more about Quanterix's Simoa® technology, visit: [www.quanterix.com/simoa-technology/](#).

About Quanterix

From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,000 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at <https://www.quanterix.com> or follow us on [Twitter](#) and [LinkedIn](#).

View source version on [businesswire.com](#): <https://www.businesswire.com/news/home/20231113873684/en/>

Media:

PAN Communications
Maya Nimnicht
510-334-6273
quanterix@pancomm.com

Investor Relations:

Ed Joyce
610-306-9917
ir@quanterix.com

Source: Quanterix Corporation